Goldman Sachs Group Inc Cabaletta Bio, Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 272,596 shares of CABA stock, worth $629,696. This represents 0.0% of its overall portfolio holdings.
Number of Shares
272,596
Previous 353,307
22.84%
Holding current value
$629,696
Previous $537,000
18.25%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CABA
# of Institutions
83Shares Held
72.8MCall Options Held
1.1MPut Options Held
14.9K-
Bain Capital Life Sciences Investors, LLC Boston, MA9.68MShares$22.4 Million7.24% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.83MShares$20.4 Million0.03% of portfolio
-
Jennison Associates LLC8.5MShares$19.6 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.36MShares$19.3 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA5MShares$11.6 Million1.86% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $67M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...